奥利万星（原 F901318）及现有系统用抗真菌药物对丝状真菌和酵母菌相的抗真菌药敏谱
Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of .
机构信息
Department of Dermatology and Venerology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China.
出版信息
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00256-21.
Abstract
antifungal susceptibility profiling of 32 clinical and environmental isolates recovered from southern China was performed against olorofim and 7 other systemic antifungals, including amphotericin B, 5-flucytosine, posaconazole, voriconazole, caspofungin, and terbinafine, using CLSI methodology. In comparison, olorofim was the most active antifungal agent against both mold and yeast phases of all tested isolates, exhibiting an MIC range, MIC, and MIC of 0.0005 to 0.002 μg/ml, 0.0005 μg/ml, and 0.0005 μg/ml, respectively.
摘要
对来自中国南方的 32 株临床和环境分离株进行了抗真菌药敏谱分析，使用 CLSI 方法对其进行了奥利伏芬和其他 7 种系统抗真菌药物（包括两性霉素 B、5-氟胞嘧啶、泊沙康唑、伏立康唑、卡泊芬净和特比萘芬）的药敏试验。相比之下，奥利伏芬对所有测试分离株的霉菌相和酵母相均为最有效的抗真菌药物，其 MIC 范围、MIC 和 MIC 分别为 0.0005 至 0.002μg/ml、0.0005μg/ml 和 0.0005μg/ml。
相似文献
1
Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of .奥利万星（原 F901318）及现有系统用抗真菌药物对丝状真菌和酵母菌相的抗真菌药敏谱
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.00256-21.
2
Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus/Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species.二氢乳清酸脱氢酶抑制剂奥洛福米对 Microascus/Scopulariopsis、Rasamsonia、Penicillium 和 Talaromyces 属具有很强的体外活性。
Mycoses. 2023 Mar;66(3):242-248. doi: 10.1111/myc.13548. Epub 2022 Dec 2.
3
In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.新型抗真菌药奥利万星对皮肤癣菌和机会性霉菌（包括青霉属和拟青霉属）的体外活性研究。
J Antimicrob Chemother. 2021 Apr 13;76(5):1229-1233. doi: 10.1093/jac/dkaa562.
4
EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.EUCAST 测定霉菌种属对奥洛福霉素（F901318）的敏感性、方法验证及 MIC 值。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00487-18. Print 2018 Aug.
5
Comparison of in vitro Susceptibilities of in Mold and Yeast Forms in Malaysia.马来西亚霉菌和酵母形态体外药敏性比较。
Infect Drug Resist. 2023 Mar 22;16:1629-1635. doi: 10.2147/IDR.S398743. eCollection 2023.
6
Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.棘白菌素类、唑类和两性霉素 B 对中国广东 HIV 感染患者马尔尼菲篮状菌酵母相的敏感性分析。
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1099-1102. doi: 10.1007/s10096-018-3222-x. Epub 2018 Mar 13.
7
In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.微量肉汤稀释法和 CLSI 方法检测olorofim（F901318）对曲霉属隐种临床分离株的体外活性。
J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078.
8
Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.显色法测定二相性真菌马尔尼菲篮状菌抗真菌药物敏感性的方法的建立和验证。
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad111.
9
In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes.奥罗非姆对尖孢镰刀菌和茄病镰刀菌种复合体临床分离株的体外活性。
Mycoses. 2021 Jul;64(7):748-752. doi: 10.1111/myc.13273. Epub 2021 Apr 4.
10
In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.采用 EUCAST 和 CLSI 方法评估奥利万星对棘白菌素属和 prolificans 属临床分离株的体外活性。
J Antimicrob Chemother. 2020 Dec 1;75(12):3582-3585. doi: 10.1093/jac/dkaa351.
引用本文的文献
1
Spectrum of clinically significant melanized fungi in NIH hospitalized patients and their antifungal susceptibility profiles.美国国立卫生研究院住院患者中具有临床意义的黑色素化真菌谱及其抗真菌药敏谱。
Med Mycol. 2025 Aug 5;63(8). doi: 10.1093/mmy/myaf072.
2
Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study.雾化吸入两性霉素B胶体分散剂联合静脉治疗侵袭性肺真菌病的疗效与安全性：一项单中心回顾性队列研究
Infect Drug Resist. 2025 Jul 10;18:3415-3425. doi: 10.2147/IDR.S519105. eCollection 2025.
3
Review of the novel antifungal drug olorofim (F901318).新型抗真菌药物奥利伏非姆（F901318）的综述。
BMC Infect Dis. 2024 Nov 7;24(1):1256. doi: 10.1186/s12879-024-10143-3.
4
Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.马尔尼菲篮状菌、粗球孢子菌和荚膜组织胞浆菌——为世界卫生组织真菌病原体优先排序提供信息的系统综述。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myad133.
5
The Role of Olorofim in the Treatment of Filamentous Fungal Infections: A Review of In Vitro and In Vivo Studies.奥洛罗芬在丝状真菌感染治疗中的作用：体外和体内研究综述
J Fungi (Basel). 2024 May 10;10(5):345. doi: 10.3390/jof10050345.
6
Amphotericin B in the Era of New Antifungals: Where Will It Stand?新型抗真菌药物时代的两性霉素B：它将何去何从？
J Fungi (Basel). 2024 Apr 10;10(4):278. doi: 10.3390/jof10040278.
7
Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.显色法测定二相性真菌马尔尼菲篮状菌抗真菌药物敏感性的方法的建立和验证。
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad111.
8
[Research advances on invasive fungal infections after burns].[烧伤后侵袭性真菌感染的研究进展]
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023 Mar 20;39(3):269-274. doi: 10.3760/cma.j.cn501225-20220523-00199.
9
An Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease.足分支霉病——一种被低估的疾病的诊断与管理策略概述
J Fungi (Basel). 2023 Jun 6;9(6):647. doi: 10.3390/jof9060647.
10
An Overlooked and Underrated Endemic Mycosis-Talaromycosis and the Pathogenic Fungus Talaromyces marneffei.被忽视和低估的地方病真菌病——马尔尼菲篮状菌病和致病真菌马尔尼菲篮状菌。
Clin Microbiol Rev. 2023 Mar 23;36(1):e0005122. doi: 10.1128/cmr.00051-22. Epub 2023 Jan 17.
本文引用的文献
1
In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.新型抗真菌药奥利万星对皮肤癣菌和机会性霉菌（包括青霉属和拟青霉属）的体外活性研究。
J Antimicrob Chemother. 2021 Apr 13;76(5):1229-1233. doi: 10.1093/jac/dkaa562.
2
New section and species in .新的章节和物种于……中
MycoKeys. 2020 Jul 7;68:75-113. doi: 10.3897/mycokeys.68.52092. eCollection 2020.
3
Innovative therapies for invasive fungal infections in preclinical and clinical development.临床前和临床开发中用于侵袭性真菌感染的创新疗法。
Expert Opin Investig Drugs. 2020 Sep;29(9):961-971. doi: 10.1080/13543784.2020.1791819. Epub 2020 Aug 6.
4
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.马杜拉分枝霉菌是真菌性肿廇的主要病原体，对奥利万星高度敏感。
J Antimicrob Chemother. 2020 Apr 1;75(4):936-941. doi: 10.1093/jac/dkz529.
5
Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.APX001A（曼戈匹克斯）和对照剂对 2017 年国际监测项目中收集的 1706 株真菌分离株的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00840-19. Print 2019 Aug.
6
In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.微量肉汤稀释法和 CLSI 方法检测olorofim（F901318）对曲霉属隐种临床分离株的体外活性。
J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590. doi: 10.1093/jac/dkz078.
7
Efficacy of Olorofim (F901318) against , , and in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.氟罗福司汀（F901318）在严重中性粒细胞减少症和慢性肉芽肿病的小鼠模型中对 、 、 的疗效。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00129-19. Print 2019 Jun.
8
The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis.奥罗托米德奥洛洛芬在中枢神经系统球孢子菌病的实验模型中有效。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00999-18. Print 2018 Sep.
9
Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.棘白菌素类、唑类和两性霉素 B 对中国广东 HIV 感染患者马尔尼菲篮状菌酵母相的敏感性分析。
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1099-1102. doi: 10.1007/s10096-018-3222-x. Epub 2018 Mar 13.
10
In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.新型抗真菌化合物F901318对澳大利亚瓶霉属和卷枝霉属真菌的体外活性
Med Mycol. 2018 Nov 1;56(8):1050-1054. doi: 10.1093/mmy/myx161.
Zotero 插件